Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to GlaxoSmithKline. GSK will pay $500 million upfront, with potential milestones reaching $12 billion, focusing on COPD treatments and collaboration on further development.